Nicholas P Restifo

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. pmc New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancer
    David F Stroncek
    Department of Transfusion Medicine, Clinical Center, NIH, Bethesda, USA
    J Transl Med 10:48. 2012
  2. doi request reprint Adoptive immunotherapy for cancer: harnessing the T cell response
    Nicholas P Restifo
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nat Rev Immunol 12:269-81. 2012
  3. pmc Immunization of patients with metastatic melanoma using both class I- and class II-restricted peptides from melanoma-associated antigens
    Giao Q Phan
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institute of Health, Bethesda, MD 20892 1502, USA
    J Immunother 26:349-56. 2003
  4. pmc IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy
    Christian S Hinrichs
    National Cancer Institute, Surgery Branch, National Institutes of Health, Bethesda, MD 20892 1502, USA
    Blood 111:5326-33. 2008
  5. pmc Cancer regression in patients after transfer of genetically engineered lymphocytes
    Richard A Morgan
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892, USA
    Science 314:126-9. 2006
  6. pmc Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen
    Laura A Johnson
    Surgery Branch, Hatfield Clinical Research Center, National Cancer Institute NIH, Bethesda, MD 20892, USA
    Blood 114:535-46. 2009
  7. pmc Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
    Giao Q Phan
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 100:8372-7. 2003
  8. doi request reprint Both CD4 and CD8 T cells mediate equally effective in vivo tumor treatment when engineered with a highly avid TCR targeting tyrosinase
    Timothy L Frankel
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 184:5988-98. 2010
  9. pmc Vaccine-stimulated, adoptively transferred CD8+ T cells traffic indiscriminately and ubiquitously while mediating specific tumor destruction
    Douglas C Palmer
    National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 173:7209-16. 2004
  10. pmc Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling
    Chrystal M Paulos
    National Cancer Institute NCI, NIH, Bethesda, Maryland 20892 1502, USA
    J Clin Invest 117:2197-204. 2007

Detail Information

Publications77

  1. pmc New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancer
    David F Stroncek
    Department of Transfusion Medicine, Clinical Center, NIH, Bethesda, USA
    J Transl Med 10:48. 2012
    ..In the future, combinations of adoptive transfer of T cells and specific vaccination against the cognate antigen can be envisaged to further enhance the effectiveness of these therapies...
  2. doi request reprint Adoptive immunotherapy for cancer: harnessing the T cell response
    Nicholas P Restifo
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nat Rev Immunol 12:269-81. 2012
    ..We also describe how new research has helped to identify the particular T cell subsets that can most effectively promote tumour eradication...
  3. pmc Immunization of patients with metastatic melanoma using both class I- and class II-restricted peptides from melanoma-associated antigens
    Giao Q Phan
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institute of Health, Bethesda, MD 20892 1502, USA
    J Immunother 26:349-56. 2003
    ..Moreover, the sequential, nonrandomized nature of patient enrollment for the two trials may account for the differences in immunologic response...
  4. pmc IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy
    Christian S Hinrichs
    National Cancer Institute, Surgery Branch, National Institutes of Health, Bethesda, MD 20892 1502, USA
    Blood 111:5326-33. 2008
    ..Thus, the efficacy of CD8(+) T cells for adoptive immunotherapy can be influenced by opposing differentiation programs conferred by IL-2 and IL-21, a finding with important implications for the development of cellular cancer therapies...
  5. pmc Cancer regression in patients after transfer of genetically engineered lymphocytes
    Richard A Morgan
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892, USA
    Science 314:126-9. 2006
    ..This study suggests the therapeutic potential of genetically engineered cells for the biologic therapy of cancer...
  6. pmc Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen
    Laura A Johnson
    Surgery Branch, Hatfield Clinical Research Center, National Cancer Institute NIH, Bethesda, MD 20892, USA
    Blood 114:535-46. 2009
    ..This trial was registered at www.ClinicalTrials.gov as NCI-07-C-0174 and NCI-07-C-0175...
  7. pmc Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
    Giao Q Phan
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 100:8372-7. 2003
    ..This study establishes CTLA-4 as an important molecule regulating tolerance to "self" antigens in humans and suggests a role for CTLA-4 blockade in breaking tolerance to human cancer antigens for cancer immunotherapy...
  8. doi request reprint Both CD4 and CD8 T cells mediate equally effective in vivo tumor treatment when engineered with a highly avid TCR targeting tyrosinase
    Timothy L Frankel
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 184:5988-98. 2010
    ..These results suggest that this highly active tyrosinase-specific TCR could be of value in adoptive cell transfer for melanoma...
  9. pmc Vaccine-stimulated, adoptively transferred CD8+ T cells traffic indiscriminately and ubiquitously while mediating specific tumor destruction
    Douglas C Palmer
    National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 173:7209-16. 2004
    ..The ability to induce ubiquitous homing and specific tumor destruction may be important in the case of noninflammatory metastatic tumor foci...
  10. pmc Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling
    Chrystal M Paulos
    National Cancer Institute NCI, NIH, Bethesda, Maryland 20892 1502, USA
    J Clin Invest 117:2197-204. 2007
    ..Thus, disruption of the homeostatic balance between the host and microbes can enhance cell-based tumor immunotherapy...
  11. pmc CTLA-4 dysregulation of self/tumor-reactive CD8+ T-cell function is CD4+ T-cell dependent
    Luca Gattinoni
    Center for Cancer Research, National Cancer Institute, National Institutes of Health, Mark O Hatfield Clinical Research Center, 10 Center Drive, Room 3 5750, Bethesda, MD 20892, USA
    Blood 108:3818-23. 2006
    ..These results indicated that CD8(+) CLTA-4(-/-) T-cell-mediated autoimmunity and tumor immunity required CD4(+) T cells in which the function was dysregulated by the absence of CTLA-4-mediated negative costimulation...
  12. pmc CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells
    Paul A Antony
    Division of Surgery, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 174:2591-601. 2005
    ..These findings reveal that Th cells can help break tolerance to a persisting self-Ag and treat established tumors through an IL-2-dependent mechanism, but requires simultaneous absence of naturally occurring T(reg) cells to be effective...
  13. pmc Cell transfer therapy for cancer: lessons from sequential treatments of a patient with metastatic melanoma
    Steven A Rosenberg
    Center for Cancer Research, Surgery Branch, National Cancer Institute, National Institute of Health, Building 10, Room 2B42, 10 Center Drive, Bethesda, Maryland 20892, USA
    J Immunother 26:385-93. 2003
    ....
  14. pmc Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells
    Claudia Wrzesinski
    Surgery Branch, National Cancer Institute, National Institute of Health, Bethesda, MD 20892, USA
    J Immunother 33:1-7. 2010
    ..Thus, increased intensity lymphodepletion triggers enhanced tumor treatment efficacy and the benefits of high-dose total body irradiation must be titrated against its risks...
  15. pmc Interleukin-2-dependent mechanisms of tolerance and immunity in vivo
    Paul A Antony
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 176:5255-66. 2006
    ..Lastly, administration of anti-IL-2 plus exogenous IL-15 to tumor-bearing mice enhanced the adoptive immunotherapy of cancer. Therefore, Th cell-derived IL-2 paradoxically controls both tolerance and immunity to a tumor/self-Ag in vivo...
  16. pmc T-cell receptor gene therapy of established tumors in a murine melanoma model
    John D Abad
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunother 31:1-6. 2008
    ..This model may be a powerful tool for evaluating future TCR gene transfer-based strategies...
  17. pmc Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity
    Christian S Hinrichs
    National Cancer Institute, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 106:17469-74. 2009
    ..These results indicate that insertion of genes that confer antitumor specificity into naïve rather than central memory CD8(+) T cells may allow superior efficacy upon adoptive transfer...
  18. pmc Tumor-specific Th17-polarized cells eradicate large established melanoma
    Pawel Muranski
    Center for Cancer Research, National Cancer Institute, National Institutes of Health, Mark O Hatfield Clinical Research Center, Bethesda, MD 20892, USA
    Blood 112:362-73. 2008
    ..This principle should be considered in designing clinical trials involving adoptive transfer-based immunotherapy of human malignancies...
  19. pmc Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer
    Rajeev K Shrimali
    Surgery Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892 1201, USA
    Cancer Res 70:6171-80. 2010
    ..These studies provide a rationale for the exploration of combining antiangiogenic agents with ACT for the treatment of patients with cancer...
  20. pmc Retinoic acid controls the homeostasis of pre-cDC-derived splenic and intestinal dendritic cells
    Christopher A Klebanoff
    Clinical Investigator Development Program and 2 Experimental Transplantation and Immunology Branch, 3 Center for Cancer Research, National Cancer Institute, National Institutes of Health NIH, Bethesda, MD 20892
    J Exp Med 210:1961-76. 2013
    ..These findings establish a critical role for RA in regulating the homeostasis of pre-DC-derived DC subsets and have implications for the management of patients with immune deficiencies resulting from malnutrition and irradiation. ..
  21. pmc High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens
    Richard A Morgan
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 171:3287-95. 2003
    ..These results suggest that lymphocytes genetically engineered to express anti-gp100 TCR may be of value in the adoptive immunotherapy of patients with melanoma...
  22. pmc Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens
    Mark E Dudley
    Surgery Branch, National Cancer Institute, NIH, Bethesda, MD 20892 1201, USA
    J Clin Oncol 26:5233-9. 2008
    ..Here, we update that study and evaluate the safety and efficacy of two increased-intensity myeloablative lymphodepleting regimens...
  23. pmc Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells
    Willem W Overwijk
    National Cancer Institute NCI, National Institute of Health, Bethesda, MD 20892 1502, USA
    J Exp Med 198:569-80. 2003
    ....
  24. pmc Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells
    Luca Gattinoni
    Center for Cancer Research, National Cancer Institute NCI, National Institutes of Health NIH, Bethesda, MD 20892, USA
    J Exp Med 202:907-12. 2005
    ..Thus, the restricted availability of homeostatic cytokines can be a contributing factor to peripheral tolerance, as well as a limiting resource for the effectiveness of tumor-specific T cells...
  25. pmc Adoptive transfer of allogeneic tumor-specific T cells mediates effective regression of large tumors across major histocompatibility barriers
    Andrea Boni
    Clinical Research Center, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 112:4746-54. 2008
    ..Taken together, these data indicate that the use of tumor-specific allogeneic CD8(+) T cells or CD4(+) can result in significant antitumor effects in the absence of measurable GVHD...
  26. pmc Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts
    Sid P Kerkar
    Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA
    Cancer Res 70:6725-34. 2010
    ..Our findings reveal an approach to genetically modify T cells to reduce the cell number needed, eliminate the need for vaccines or systemic IL-2, and improve immunotherapy efficacy based on adoptive transfer of gene-engineered T cells...
  27. pmc Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy
    Christian S Hinrichs
    National Cancer Institute, Bethesda, MD, USA
    Blood 117:808-14. 2011
    ..Thus, these data suggest that naive cells resist terminal differentiation, or "exhaustion," maintain high replicative potential, and therefore may be the superior subset for use in adoptive immunotherapy...
  28. pmc Bcl-2 overexpression enhances tumor-specific T-cell survival
    Jehad Charo
    Surgery Branch, National Cancer Institute, Bethesda, Maryland 20892, USA
    Cancer Res 65:2001-8. 2005
    ..Our data suggest that adoptive immunotherapy approaches to the treatment of cancer patients may be enhanced using Bcl-2-modified tumor-reactive T cells...
  29. pmc IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors
    Sid P Kerkar
    Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892 1502, USA
    J Clin Invest 121:4746-57. 2011
    ....
  30. pmc Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma
    Steven A Rosenberg
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 175:6169-76. 2005
    ..Further, the induction of even high levels of antitumor T cells may be insufficient to alter tumor progression...
  31. pmc Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma
    Steven A Rosenberg
    Center for Cancer Research, Surgery Branch, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 9:2973-80. 2003
    ..The immunogenicity of these constructs was studied using peripheral blood mononuclear cells to measure epitope-specific release of IFN-gamma...
  32. pmc Extrathymic generation of tumor-specific T cells from genetically engineered human hematopoietic stem cells via Notch signaling
    Yangbing Zhao
    Surgery Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892 1201, USA
    Cancer Res 67:2425-9. 2007
    ..The genetic manipulation of HSCs has broad implications for ACT of cancer...
  33. pmc Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells
    Christopher A Klebanoff
    Howard Hughes Medical Institute, National Institutes of Health Research Scholars Program, Bethesda, MD 20814, USA
    Proc Natl Acad Sci U S A 102:9571-6. 2005
    ..Thus, tumor-reactive CD8+ T cell populations with the phenotypic and functional attributes of T(CM) may be superior to T(EM)/effector T cells for adoptive immunotherapies using concomitant tumor-antigen vaccination...
  34. pmc Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells
    Luca Gattinoni
    Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892 1502, USA
    J Clin Invest 115:1616-26. 2005
    ..These findings suggest that the current methodology for selecting T cells for transfer is inadequate and provide new criteria for the generation and the screening of optimal lymphocyte populations for adoptive immunotherapy...
  35. pmc Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4
    Peter Attia
    Surgery Branch, National Cancer Institute, National Institutes of Health, CRC, Room 3W 3940, 10 Center Dr, Bethesda, MD 20892 1201, USA
    J Clin Oncol 23:6043-53. 2005
    ..We have now treated 56 patients to evaluate two different dose schedules of anti-CTLA-4 and to explore the relationship between autoimmunity and tumor regression...
  36. pmc Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice
    Dhanalakshmi Chinnasamy
    Surgery Branch, National Cancer Institute, Clinical Research Center, Bethesda, Maryland 20892, USA
    J Clin Invest 120:3953-68. 2010
    ..T cells transduced with VEGFR-2 CAR showed durable and increased tumor infiltration, correlating with their antitumor effect. This approach provides a potential method for the gene therapy of a variety of human cancers...
  37. pmc Type 17 CD8+ T cells display enhanced antitumor immunity
    Christian S Hinrichs
    National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892, USA
    Blood 114:596-9. 2009
    ..This report is the first description of a cancer therapy with IL-17-secreting CD8(+) T cells. These findings have implications for the improvement of CD8(+) T cell-based adoptive immunotherapy...
  38. pmc Glucocorticoids do not inhibit antitumor activity of activated CD8+ T cells
    Christian S Hinrichs
    National Cancer Institute NCI, National Institutes of Health NIH, Bethesda, Maryland 20892 1502, USA
    J Immunother 28:517-24. 2005
    ..Finally, because glucocorticoids had no effect on tumor regression in this model, it may be possible to use glucocorticoids in some patients receiving ACT-based immunotherapy regimens...
  39. pmc Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity
    Douglas C Palmer
    National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 105:8061-6. 2008
    ..These findings have particular importance for immunotherapies directed against self-antigens and highlight the need for targeting unique tumor antigens not expressed in critical tissues...
  40. pmc Programming tumor-reactive effector memory CD8+ T cells in vitro obviates the requirement for in vivo vaccination
    Christopher A Klebanoff
    Howard Hughes Medical Institute National Institutes of Health Research Scholars Program, Bethesda, MD, USA
    Blood 114:1776-83. 2009
    ..These findings extend the phenomenon of a programmable effector response to memory CD8(+) T cells and have major implications for the design of current adoptive-cell transfer trials...
  41. pmc Repression of the DNA-binding inhibitor Id3 by Blimp-1 limits the formation of memory CD8+ T cells
    Yun Ji
    Center for Cancer Research, National Cancer Institute, US National Institutes of Health, Bethesda, Maryland, USA
    Nat Immunol 12:1230-7. 2011
    ..Our findings identify the Blimp-1-Id3-E2A axis as a key molecular switch that determines whether effector CD8(+) T cells are programmed to die or enter the memory pool...
  42. pmc Th17 cells are long lived and retain a stem cell-like molecular signature
    Pawel Muranski
    National Cancer Institute, Bethesda, MD 20892, USA
    Immunity 35:972-85. 2011
    ..Thus, Th17 cells are not always short lived and are a less-differentiated subset capable of superior persistence and functionality...
  43. pmc Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes
    Mark E Dudley
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20902, USA
    Science 298:850-4. 2002
    ..This approach presents new possibilities for the treatment of patients with cancer as well as patients with human immunodeficiency virus-related acquired immunodeficiency syndrome and other infectious diseases...
  44. pmc IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells
    Christopher A Klebanoff
    Howard Hughes Medical Institute National Institutes of Health Research Scholars Program, Bethesda, MD 20814, USA
    Proc Natl Acad Sci U S A 101:1969-74. 2004
    ..These results provide several avenues for improving adoptive immunotherapy of cancer in patients...
  45. pmc Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells
    Luca Gattinoni
    Center for Cancer Research, National Cancer Institute, US National Institutes of Health, Bethesda, Maryland, USA
    Nat Med 15:808-13. 2009
    ..These findings reveal a key role for Wnt signaling in the maintenance of 'stemness' in mature memory CD8(+) T cells and have major implications for the design of new vaccination strategies and adoptive immunotherapies...
  46. pmc Toll-like receptors in tumor immunotherapy
    Chrystal M Paulos
    National Cancer Institute, NIH, Mark O Hatfield Clinical Research Center, Bethesda, Maryland 20892 1502, USA
    Clin Cancer Res 13:5280-9. 2007
    ..We also discuss alternate regimens to chemotherapy or TBI, which might be used to safely treat patients with advanced disease and promote tumor regression...
  47. pmc Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 T cells
    Claudia Wrzesinski
    National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    J Clin Invest 117:492-501. 2007
    ..These findings indicate that CD8(+) T cell-mediated tumor responses can be efficiently driven by HSCs in the myeloablative setting and have substantial implications for the design of new antitumor immunotherapies...
  48. pmc Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice
    Christopher A Klebanoff
    Center for Cancer Research CCR, National Cancer Institute NCI, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 17:5343-52. 2011
    ..However, the relative contributions of each these individual components to the magnitude of the antitumor response have yet to be quantified...
  49. pmc Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy
    Steven A Rosenberg
    Surgery Branch, National Cancer Institute, NIH, Bethesda, Maryland, USA
    Clin Cancer Res 17:4550-7. 2011
    ..We investigated the ability of adoptive cell transfer utilizing autologous tumor-infiltrating lymphocytes (TIL) to mediate durable complete regressions in heavily pretreated patients with metastatic melanoma...
  50. pmc The in vivo expansion rate of properly stimulated transferred CD8+ T cells exceeds that of an aggressively growing mouse tumor
    Leroy N Hwang
    Clinical Research Center, National Cancer Institute NIH, Building CRC, Bethesda, MD 20892, USA
    Cancer Res 66:1132-8. 2006
    ..When appropriately stimulated, tumor-reactive T-cell expansion can far exceed the growth of even an aggressively growing mouse tumor...
  51. pmc Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma
    Mark E Dudley
    Surgery Branch, National Cancer Institute, NIH, CRC 3 3940, 10 Center Dr MSC 1201, Bethesda MD 20892 1202, USA
    J Clin Oncol 23:2346-57. 2005
    ..We investigated the combination of lymphodepleting chemotherapy followed by the adoptive transfer of autologous tumor reactive lymphocytes for the treatment of patients with refractory metastatic melanoma...
  52. pmc Sensitization of B16 tumor cells with a CXCR4 antagonist increases the efficacy of immunotherapy for established lung metastases
    Chih Hung Lee
    Dermatology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892 1908, USA
    Mol Cancer Ther 5:2592-9. 2006
    ..In vivo, T22 synergizes with cyclophosphamide or anti-CTLA4 mAb in the treatment of established lung metastases, suggesting a novel strategy for augmenting the efficacy of immunotherapy...
  53. pmc Normal tissue depresses while tumor tissue enhances human T cell responses in vivo to a novel self/tumor melanoma antigen, OA1
    Christopher E Touloukian
    National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 170:1579-85. 2003
    ..Thus, the tumor-bearing state reverses, in part, the tolerance of T cells that results from the normal expression of tissue differentiation Ags...
  54. pmc Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines
    Franz O Smith
    Surgery Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892 1201, USA
    Clin Cancer Res 14:5610-8. 2008
    ..v. interleukin-2 (IL-2) given either alone or in combination with a variety of melanoma vaccines...
  55. pmc Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1
    Paul F Robbins
    National Institutes of Health, National Cancer Institute, Surgery Branch, Bethesda, MD 20892 1201, USA
    J Clin Oncol 29:917-24. 2011
    ....
  56. pmc High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation
    Yangbing Zhao
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Mol Ther 13:151-9. 2006
    ..The results of this study indicate that mRNA electroporation provides a powerful tool to introduce genes into both human and murine primary T lymphocytes...
  57. doi request reprint Modulating the differentiation status of ex vivo-cultured anti-tumor T cells using cytokine cocktails
    Shicheng Yang
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, Building 10, CRC 3 W 3864, Bethesda, MD, 20892, USA
    Cancer Immunol Immunother 62:727-36. 2013
    ..The methodology that we developed for generating a less-differentiated anti-tumor CD8+ T cells ex vivo may be ideal for the adoptive immunotherapy of cancer...
  58. pmc Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen
    Steven A Rosenberg
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1502, USA
    Hum Gene Ther 14:709-14. 2003
    ..We were thus unable to demonstrate significant clinical or immunologic responses to plasmid DNA encoding the "self" nonmutated gp100 tumor antigen...
  59. pmc Genetic engineering of murine CD8+ and CD4+ T cells for preclinical adoptive immunotherapy studies
    Sid P Kerkar
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunother 34:343-52. 2011
    ..These results indicate that preclinical murine models of adoptive immunotherapies are more practical using γ-retroviral rather than lentiviral vectors...
  60. pmc In vitro generated anti-tumor T lymphocytes exhibit distinct subsets mimicking in vivo antigen-experienced cells
    Shicheng Yang
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892, USA
    Cancer Immunol Immunother 60:739-49. 2011
    ....
  61. pmc Altered CD8(+) T-cell responses when immunizing with multiepitope peptide vaccines
    Steven A Rosenberg
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Immunother 29:224-31. 2006
    ....
  62. pmc Different adjuvanticity of incomplete freund's adjuvant derived from beef or vegetable components in melanoma patients immunized with a peptide vaccine
    Steven A Rosenberg
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1201, USA
    J Immunother 33:626-9. 2010
    ..A survey of ongoing clinical trials listed in ClinicalTrials.gov revealed 36 trials currently accruing patients that are using the olive-derived Montanide ISA 51 IFA...
  63. pmc Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy
    Richard A Morgan
    Surgery Branch, National Cancer Institute, Bethesda, MD 20892, USA
    J Immunother 36:133-51. 2013
    ....
  64. pmc Poor immunogenicity of a self/tumor antigen derives from peptide-MHC-I instability and is independent of tolerance
    Zhiya Yu
    Surgery Branch, National Cancer Institute NIH, Building 10, Bethesda, MD 20892, USA
    J Clin Invest 114:551-9. 2004
    ..These findings indicate that the poor immunogenicity of some self/tumor antigens is due to the instability of the peptide-MHC complex rather than to the continual deletion or tolerization of self-reactive T cells...
  65. doi request reprint The stoichiometric production of IL-2 and IFN-γ mRNA defines memory T cells that can self-renew after adoptive transfer in humans
    Anran Wang
    Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20817, USA
    Sci Transl Med 4:149ra120. 2012
    ..These findings demonstrate the favorable engraftment fitness for human T(CM)-derived clones, but further efforts to improve their antitumor efficacy are still necessary...
  66. pmc CD8+ enriched "young" tumor infiltrating lymphocytes can mediate regression of metastatic melanoma
    Mark E Dudley
    Surgery Branch and Radiation Oncology Branch, National Cancer Institute, Bethesda, Maryland 20892 1201, USA
    Clin Cancer Res 16:6122-31. 2010
    ..However, the generation of a unique tumor-reactive TIL culture for each patient may be prohibitively difficult. We therefore investigated the clinical and immunologic impact of unscreened, CD8+ enriched "young" TIL...
  67. pmc Ocular and systemic autoimmunity after successful tumor-infiltrating lymphocyte immunotherapy for recurrent, metastatic melanoma
    Steven Yeh
    National Eye Institute, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20814, USA
    Ophthalmology 116:981-989.e1. 2009
    ..To describe the ophthalmic and systemic autoimmune findings after successful adoptive cell transfer of ex vivo expanded, autologous tumor-reactive tumor-infiltrating lymphocytes (TIL) for metastatic melanoma...
  68. pmc Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment
    Ling Zhang
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Mol Ther 19:751-9. 2011
    ..Notably, this targeted and controlled IL-12 treatment was without toxicity. Taken together, our results suggest that using the NFAT.hIL12.PA2 vector might be a promising approach to enhance adoptive cancer immunotherapy...
  69. pmc Evaluation of prime/boost regimens using recombinant poxvirus/tyrosinase vaccines for the treatment of patients with metastatic melanoma
    Kimberly R Lindsey
    Surgery Branch, National Cancer Institute, Center for Cancer Research, NIH, Bethesda, Maryland, USA
    Clin Cancer Res 12:2526-37. 2006
    ..Two clinical trials were conducted to evaluate the clinical efficacy and immunologic impact of vaccination against the tyrosinase protein plus systemic interleukin 2 (IL-2) administration in patients with advanced metastatic melanoma...
  70. pmc Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function
    Rong Zeng
    Laboratory of Molecular Immunology, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Exp Med 201:139-48. 2005
    ..Thus, our studies reveal that IL-21 potently regulates CD8+ T cell expansion and effector function, primarily in a synergistic context with IL-15...
  71. pmc Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy
    Christopher A Klebanoff
    Howard Hughes Medical Institute National Institutes of Health Research Scholars Program, Bethesda, MD 20814, USA
    Trends Immunol 26:111-7. 2005
  72. pmc Bedside to bench and back again: how animal models are guiding the development of new immunotherapies for cancer
    Steven E Finkelstein
    National Cancer Institute, National Institutes of Health, Building 10, Room 2B 46, 10 Center Drive, Bethesda, MD 20892, USA
    J Leukoc Biol 76:333-7. 2004
    ..Complete responders frequently develop autoimmunity with vitiligo at the former tumor site that often spreads to involve the whole coat. These findings have important implications for the design of immunotherapy trials in humans...
  73. pmc Type I Interferons are essential for the efficacy of replicase-based DNA vaccines
    Wolfgang W Leitner
    Clinical Research Center, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Vaccine 24:5110-8. 2006
    ..These results suggest a central role for Type I IFNs in the mechanism of replicase-based DNA vaccines and indicate that vaccines can be enhanced by enabling their capacity to triggering innate anti-viral defense pathways...
  74. pmc Collapse of the tumor stroma is triggered by IL-12 induction of Fas
    Sid P Kerkar
    Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    Mol Ther 21:1369-77. 2013
    ....
  75. doi request reprint A TCR targeting the HLA-A*0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer
    Nachimuthu Chinnasamy
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 186:685-96. 2011
    ..On the basis of these results, a clinical trial is planned in which patients bearing a variety of tumor histologies will receive autologous PBLs that have been transduced with this optimized anti-MAGE-A3 TCR...
  76. pmc Pharmacologic induction of CD8+ T cell memory: better living through chemistry
    Luca Gattinoni
    Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Sci Transl Med 1:11ps12. 2009
    ..These findings raise the exciting new possibility of using small molecules, many of which are already approved for human use, for the pharmacologic induction of immunologic memory...
  77. pmc Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells
    James N Kochenderfer
    Surgery Branch of the National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 116:3875-86. 2010
    ..Our results demonstrated impressive antilymphoma activity and profound destruction of normal B cells caused by anti-CD19-CAR-transduced T cells in a clinically relevant murine model...